Enveda Biosciences
PrivateLast Round
Series E
Sep 23, 2026
Est. Valuation
$2B
Total Funding Raised
$911.9M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Enveda Biosciences is a biotechnology company that utilizes an AI-powered drug discovery platform to analyze natural samples for chemical structure and biological activity to develop novel small-molecule medicines.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Medical AI, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Foundation
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Enveda Biosciences Comparables
Compare Enveda Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Insitro | 81% | |
| Valo Health | 81% | |
| Terray Therapeutics | 80% |
Enveda Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series E | Sep 23, 2026 | ||||
| Series D | Sep 4, 2025 | ||||
| Series C Extension | Feb 26, 2025 | ||||
| Series C | Nov 21, 2024 | ||||
| Series B Extension | Jun 14, 2024 | ||||
Series B Extension | Apr 20, 2023 |
Key People
Founding team and executive leadership
Enveda Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| S32 | Series B Extension |
| Surveyor Capital | Series E |
| Alderline Group | Series E |
| ICONIQ Capital | Series E |
| Digitalis Ventures | Series E |
| Lingotto | Series B Extension, Series D, Series C |
| Global Village | Seed, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 23, 2026
$311M round led by Catalio Capital Management.
- Apr 8, 2026
ENV-294 is one of the lead assets in clinical trials.
Recent news
Latest coverage and updates
- receives_financingSep 24, 2026
Enveda received financing of $311M in Series C on Jul 1st '26.
- has_valuationSep 24, 2026
Enveda had valuation of $2B on Sep 23rd '26.
- hiresSep 23, 2026
Enveda hired George Petrocheilos as board on Sep 23rd '26.
- is_developingSep 23, 2026
Enveda is developing PRISM on Jul 1st '26.
- launchesAug 24, 2026
Enveda launched compound that mimics the physiological effects of exercise on Aug 24th '26.
Enveda Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Enveda Biosciences's valuation, stock price, and market status.
Is Enveda a public or private company?
Enveda is a private company.
What is the current stock price of Enveda?
Enveda is a private company with no public stock price. No recent secondary market data is available.
How much is Enveda worth (valuation)?
Enveda's valuation is estimated at $1.0B based on funding round data.
Can I buy Enveda stock?
Enveda shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Enveda's last funding round?
Enveda's most recent funding round was Series D on September 4, 2025.
Who are the main investors in Enveda?
Key investors in Enveda include Lux Capital, Premji Invest (US), Dimension, FPV Ventures, Kinnevik.
Will Enveda IPO soon?
No public IPO plans have been announced for Enveda.
How can I track Enveda secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Enveda's secondary market activity and sign up for updates.